In conclusion, given nicotine’s effects in humans, experimental support for α7nAChR involvement in eating behavior regulation, and early evidence of α7nAChR agonist effects in animal studies, the α7nAChR may represent a promising new therapeutic target for weight management and the treatment of obesity in humans. This evidence concerns the gene CHRNA7 and obesity due to melanocortin 4 receptor deficiency.